Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Vaccinations in Immunocompromised Persons

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Indication for hepatitis A and/or tetanus vaccination according to Swiss Federal Office of Public Health recommendations~* Male and female rheumatic patients with rheumatoid arthritis or axial spondyloarthritis (ankylosing spondylitis, axial psoriatic arthritis, axial undifferentiated spondyloarthritis, enteropahtic arthritis) or peripheral psoriatic arthritis or vasculitis (Behçet's disease or ANCA-associated vasculitis) or male and female healthy participants ≥ 18 years~* Signed Informed Consent after being informed~Exclusion Criteria:~* Known hypersensitivity to a vaccine ingredient~* Estimated patient survival below 1 year~* Active malignant or active infectious disease~* Drug/alcohol abuse~* Insufficient understanding of local language

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healthy controls (Type: None): If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 319 healthy controls will be enrolled and will receive hepatitis A and/or tetanus vaccination
- Patients with rheumatoid arthritis (Type: None): If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with rheumatoid arthritis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
- Patients with axial spondylarthritis (Type: None): If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with axial spondylarthritis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
- Patients with vasculitis (Type: None): If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with vasculitis will be enrolled and will receive hepatitis A and/or tetanus vaccination.

Based on this trial design, predict the completion outcome and termination type (if applicable).